Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy

Robert I. Griffiths, Miriam Bar-Din, Catherine H. MacLean, Erin M. Sullivan, Robert J. Herbert, Edward H. Yelin

Research output: Contribution to journalArticle

Abstract

Objective. To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drug (DMARD) therapies. Methods. Using managed care organization data, we identified members who (a) were prescribed any DMARD therapy for two consecutive months between July 1993 and February 1998, (b) were aged ≥18 years, (c) had ≥6 months of DMARD-free enrollment prior to the first DMARD, and (d) had a diagnosis of RA. Results. The average age of the cohort (n = 571) was 51 years, and 70% were women. Mean duration of enrollment following initiation of DMARD therapy (observation period) was 19.5 months; 28.8% of patients switched DMARD regimens. The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medical services. Monthly RA-coded costs varied by DMARD: hydroxychloroquine $227 (n = 252), methotrexate $340 (n = 185); sulfasalazine $233 (n = 49), and other mono/combination therapy $425 (n = 85) (P = 0.001). Conclusion. Costs of RA-coded care in patients receiving DMARDs are low and vary by DMARD.

Original languageEnglish (US)
Pages (from-to)213-226
Number of pages14
JournalArthritis Care and Research
Volume13
Issue number4
StatePublished - 2000

Fingerprint

Antirheumatic Agents
Rheumatoid Arthritis
Costs and Cost Analysis
Drug Therapy
Hydroxychloroquine
Sulfasalazine
Cost of Illness
Managed Care Programs
Methotrexate
Patient Care
Observation
Organizations

Keywords

  • Costs
  • Drug therapy
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Griffiths, R. I., Bar-Din, M., MacLean, C. H., Sullivan, E. M., Herbert, R. J., & Yelin, E. H. (2000). Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy. Arthritis Care and Research, 13(4), 213-226.

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy. / Griffiths, Robert I.; Bar-Din, Miriam; MacLean, Catherine H.; Sullivan, Erin M.; Herbert, Robert J.; Yelin, Edward H.

In: Arthritis Care and Research, Vol. 13, No. 4, 2000, p. 213-226.

Research output: Contribution to journalArticle

Griffiths, RI, Bar-Din, M, MacLean, CH, Sullivan, EM, Herbert, RJ & Yelin, EH 2000, 'Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy', Arthritis Care and Research, vol. 13, no. 4, pp. 213-226.
Griffiths, Robert I. ; Bar-Din, Miriam ; MacLean, Catherine H. ; Sullivan, Erin M. ; Herbert, Robert J. ; Yelin, Edward H. / Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy. In: Arthritis Care and Research. 2000 ; Vol. 13, No. 4. pp. 213-226.
@article{b0fa9548efa642269329dffd89adf71b,
title = "Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy",
abstract = "Objective. To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drug (DMARD) therapies. Methods. Using managed care organization data, we identified members who (a) were prescribed any DMARD therapy for two consecutive months between July 1993 and February 1998, (b) were aged ≥18 years, (c) had ≥6 months of DMARD-free enrollment prior to the first DMARD, and (d) had a diagnosis of RA. Results. The average age of the cohort (n = 571) was 51 years, and 70{\%} were women. Mean duration of enrollment following initiation of DMARD therapy (observation period) was 19.5 months; 28.8{\%} of patients switched DMARD regimens. The average monthly cost of care was $853, of which $294 (34{\%}) was for RA-coded medical services. Monthly RA-coded costs varied by DMARD: hydroxychloroquine $227 (n = 252), methotrexate $340 (n = 185); sulfasalazine $233 (n = 49), and other mono/combination therapy $425 (n = 85) (P = 0.001). Conclusion. Costs of RA-coded care in patients receiving DMARDs are low and vary by DMARD.",
keywords = "Costs, Drug therapy, Rheumatoid arthritis",
author = "Griffiths, {Robert I.} and Miriam Bar-Din and MacLean, {Catherine H.} and Sullivan, {Erin M.} and Herbert, {Robert J.} and Yelin, {Edward H.}",
year = "2000",
language = "English (US)",
volume = "13",
pages = "213--226",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy

AU - Griffiths, Robert I.

AU - Bar-Din, Miriam

AU - MacLean, Catherine H.

AU - Sullivan, Erin M.

AU - Herbert, Robert J.

AU - Yelin, Edward H.

PY - 2000

Y1 - 2000

N2 - Objective. To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drug (DMARD) therapies. Methods. Using managed care organization data, we identified members who (a) were prescribed any DMARD therapy for two consecutive months between July 1993 and February 1998, (b) were aged ≥18 years, (c) had ≥6 months of DMARD-free enrollment prior to the first DMARD, and (d) had a diagnosis of RA. Results. The average age of the cohort (n = 571) was 51 years, and 70% were women. Mean duration of enrollment following initiation of DMARD therapy (observation period) was 19.5 months; 28.8% of patients switched DMARD regimens. The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medical services. Monthly RA-coded costs varied by DMARD: hydroxychloroquine $227 (n = 252), methotrexate $340 (n = 185); sulfasalazine $233 (n = 49), and other mono/combination therapy $425 (n = 85) (P = 0.001). Conclusion. Costs of RA-coded care in patients receiving DMARDs are low and vary by DMARD.

AB - Objective. To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drug (DMARD) therapies. Methods. Using managed care organization data, we identified members who (a) were prescribed any DMARD therapy for two consecutive months between July 1993 and February 1998, (b) were aged ≥18 years, (c) had ≥6 months of DMARD-free enrollment prior to the first DMARD, and (d) had a diagnosis of RA. Results. The average age of the cohort (n = 571) was 51 years, and 70% were women. Mean duration of enrollment following initiation of DMARD therapy (observation period) was 19.5 months; 28.8% of patients switched DMARD regimens. The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medical services. Monthly RA-coded costs varied by DMARD: hydroxychloroquine $227 (n = 252), methotrexate $340 (n = 185); sulfasalazine $233 (n = 49), and other mono/combination therapy $425 (n = 85) (P = 0.001). Conclusion. Costs of RA-coded care in patients receiving DMARDs are low and vary by DMARD.

KW - Costs

KW - Drug therapy

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0033813624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033813624&partnerID=8YFLogxK

M3 - Article

C2 - 14635276

AN - SCOPUS:0033813624

VL - 13

SP - 213

EP - 226

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -